Topamax (TO-pa-max) is approved as an add-on medication for adults and children (2 to 16 years old) with partial seizures with or without secondary generalization or primary generalized tonic-clonic seizures and for seizures associated with the Lennox-Gastaut syndrome. It has been reported to be successful in myoclonic epilepsy and may have a role in the treatment of infantile spasms.
Reported side effects include difficulty with concentration, speech and language problems, cognitive slowing, drowsiness, dizziness, tingling of distal extremities/face, unsteadiness and fatigue. Side effects are more likely with higher starting doses and quickly increasing doses. Decreased appetite, weight loss and kidney stones have been reported.
Safety in pregnancy has not been established. Women who are taking this medication and who wish to become pregnant should discuss treatment options with their physicians before the pregnancy begins.